Trial Profile
A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Aug 2021
Price :
$35
*
At a glance
- Drugs Rifamycin (Primary)
- Indications Irritable bowel syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Cosmo Technologies
- 11 Jan 2021 Primary endpoint (Proportion of subjects who achieved success, defined as an adequate relief of both abdominal pain and diarrhea at the end of the first week of treatment (at least 30% decrease in pain score and at least 50% reduction in the number of days per week with diarrhea)) has been met, according to a Cosmo Pharmaceuticals media release.
- 11 Jan 2021 Results presented in a Cosmo Pharmaceuticals media release.
- 11 Jan 2021 Results presented in a RedHill Biopharma media release.